Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain

Flush with fresh funding, the stem cell play’s overhauled management is supremely confident of striking a partnering deal in Japan pertaining to its lead osteoarthritis treatment Progenza.

This confident assertion - accompanied by a $5.54 million capital raising - lifts a burden of guilt for your columnist, who late last year put the mozz on the company by describing its board - barely changed since the company’s listing in 2013 - as remarkably stable.

Read the full article via Stockhead here.

90 Seconds With...Dr Alan Dunton

Regeneus (ASX:RGS) is a leading pain management and clinical-stage regenerative medicine company.

In a bid to fast-track its push for global growth, the company recently appointed two experienced leaders in life sciences and biotechnology to its board, including Dr Dunton.

Dr Dunton is a pharmaceutical and biotechnology industry leader with over 35 years of experience in senior company leadership roles, spanning pharmaceutical research and development to private biotechnology companies focussed on prescriptive treatment and the commercialisation of over-the-counter drugs on a global scale.

Of the appointment, Regeneus CEO Leo Lee said: “Dr Dunton’s wealth of knowledge in commercialising drugs on a global scale places Regeneus in a strong position to create a huge uplift in value for shareholders.”

Stockhead spoke with Dr Dunton about his recent appointment and the potential of Regeneus’ cell therapy technology.

Watch Dr Dunton's full video interview with Stockhead here.

Positive promise of stem cell therapy

Regenerating every cell, tissue or organ in the body, curing genetic disorders and chronic diseases, alleviating pain and delaying the onset of ageing, these are the altruistic promises of stem cell therapy.

A key driver of the regenerative medicine market, stem cell therapy’s infinite applications have biotechs racing to the clinical trial finishing line. More than 600 stem cell patents have been filed within Australia in the last five years and over 500 companies globally are involved in stem cell product development.

Read the full article in The Australian Financial Review here.

Regeneus prepares for global growth with appointment of life sciences industry leaders

ASX listed regenerative medicine company Regeneus (ASX: RGS) has today announced the appointments of John Chiplin, PhD and Alan W. Dunton, M.D. to its board of directors.

Joining Regeneus as Non-Executive Directors, both Chiplin and Dunton bring significant experience in leading and growing large-scale life sciences and biotechnology companies internationally.

The appointments come at a time when Regeneus is seeking to roll out its global growth strategy targeting the global pain market.

Read the full article published bu Star Investing here.

90 Seconds With...Leo Lee

Regeneus (ASX:RGS) announced this week that Dr John Chiplin, PhD and Dr Alan Dunton, M.D. have joined its board to support the company’s global growth strategy.

Dr Chiplin is Managing Director of Newstar Ventures and has significant operational, investment and transactions experienced in the international life science and technology industries.

Previously, he’s served as CEO at three publicly-listed software, biotechnology and cancer immunotherapy companies.

Dr Dunton is a senior pharmaceutical and biotechnology industry leader with experience across large pharmaceutical research and development organisations as well as private biotech companies focused on prescriptive treatment and the development and commercialisation of over-the-counter drugs on a global and local scale.

Regeneus’ CEO Leo Lee spoke with Stockhead about the potential impact of the new appointments.

Watch Leo's full video interview with Stockhead here.

Regeneus ramps up global focus with addition of industry leaders

Regeneus Ltd (ASX: RGS), a leading pain management and clinical-stage regenerative medicine company, has fast-tracked its push for global growth following the appointments of two highly successful leaders in life sciences and biotechnology to its board.

Read the full article on Stockhead here.

Regeneus' newly-appointed CEO Leo Lee discusses strategic plans for growth

Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company's operations, and the wider scientific field.

The company holds a number of patents, and is focusing on global expansion, as it advances treatments in the areas of osteoarthritis, cancer, and dermatology.

Watch Leo's full interview with Proactive Investors here.